Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bateman, A.
Right arrow Articles by Vile, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bateman, A.
Right arrow Articles by Vile, R. G.
[Cancer Research 60, 1492-1497, March 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Fusogenic Membrane Glycoproteins As a Novel Class of Genes for the Local and Immune-mediated Control of Tumor Growth1

Andrew Bateman, Francis Bullough, Stephen Murphy, Lisa Emiliusen, Dimitri Lavillette, François-Loic Cosset, Roberto Cattaneo, Stephen J. Russell and Richard G. Vile2

Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905 [A. B., S. M., L. E., R. C., S. J. R., R. G. V.]; Cambridge Genetics Limited, CB4 OF9 Cambridge, United Kingdom [F. B.]; and Vectorologie Retrovirale et Therapie Genique, INSERM U412–Unite de Virologie Humaine Ecole Normale Superieure de Lyon, 69364 Lyon Cedex 07, France [D. L., F-L. C.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
We report here the use of viral fusogenic membrane glycoproteins (FMGs) as a new class of therapeutic genes for the control of tumor growth. FMGs kill cells by fusing them into large multinucleated syncytia, which die by sequestration of cell nuclei and subsequent nuclear fusion by a mechanism that is nonapoptotic, as assessed by multiple criteria. Direct and bystander killing of three different FMGs were at least one log more potent than that of herpes simplex virus thymidine kinase or cytosine deaminase suicide genes. Transduction of human tumor xenografts with plasmid DNA prevented tumor outgrowth in vivo, and cytotoxicity could be regulated through transcriptional targeting. Syncytial formation is accompanied by the induction of immunostimulatory heat shock proteins, and tumor-associated FMG expression in immunocompetent animals generated specific antitumor immunity.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Ideally, the transfer of therapeutic genes into tumor cells should lead both to direct local cell destruction and to activation of antitumor immunity to clear tumor deposits to which the genes cannot be delivered. The genes most commonly used in clinical trials for the control of local tumor growth have been the suicide gene/prodrug systems such as HSVtk3 /GCV or cytosine deaminase/5-fluorocytosine system (1) . Importantly, these systems have local bystander effects (1) that are crucial to compensate for the relatively poor efficiencies of gene transfer that are currently possible (2) . Other classes of genes have also been effective via nonspecific immune activation and inflammatory killing (3) . In addition, gene transfer has been successful in stimulating tumor cell-specific immune responses (4) , often through cross priming of host professional APCs with released tumor antigens (5 , 6) . In this respect, we have shown that HSVtk-mediated tumor cell killing in vivo can generate potent antitumor immunity (7) , in part via induction of heat shock protein expression, which both attracts APCs to the tumor site and promotes their cross-priming with tumor antigens (8 , 9) . However, both better delivery systems and more effective genes are clearly still required to improve the efficiency of both local tumor control and of antitumor immune responses. In this respect, several different viruses kill their target cells by inducing fusion between infected and noninfected cells via the interaction of the viral envelope with its cellular receptor (10) . Here we report that this activity of viral FMG can be exploited therapeutically to kill tumor cells more efficiently than conventional suicide genes and that they do so by mechanisms that are also highly immunostimulatory.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
FMG and Suicide Gene Vectors.
All genes were subcloned into the pCR3.1 vector (Invitrogen) to be expressed from the same CMV promoter. Transfections were carried out using the Profection (calcium phosphate coprecipitation) method (Promega, Madison, WI) or the Efectene lipid reagent (Qiagen).

Apoptosis Detection.
Cells were cultured in Labtek chamber slides (Nalge Nunc International), plated at a density of 1 x 105/chamber, and transfected on day 0. Cells were collected on days 1–4, washed with PBS, and fixed with 2% paraformaldehyde. Then cells were washed and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate. Next, the cells were washed, incubated for 60 min with TUNEL reaction mixture (In situ Cell Death Detection kit, fluorescein; Boehringer Mannheim), washed again, air dried, and mounted with Vectashield (Vector Laboratories) containing 2 µg/ml 4',6-diamidine-2'-phenylindole dihydrochloride (Boehringer Mannheim).

hsp Detection Using RT-PCR.
RNA was prepared from transfected cells with RNAzol (Biogenesis, Bournemouth, United Kingdom). RNA concentrations were measured, and 1 µg of total cellular RNA was reverse transcribed in a 20-µl volume using oligo-(dT) as a primer and Moloney murine leukemia virus reverse transcriptase (Pharmacia LKB Biotechnology, Milton Keynes, United Kingdom). A cDNA equivalent of 1 ng of RNA was amplified by the PCR using primers specific for inducible human hsp70, gp96, or glyceraldehyde-3-phosphate dehydrogenase (details of primers available on request). In all experiments, a mock PCR (without added DNA) was performed to exclude contamination. To exclude carry-over of genomic DNA during the RNA preparation step, controls were also carried out in which the reverse transcriptase enzyme was omitted.

In Vivo Studies.
All procedures were approved by the Institutional Animal Care and Use Committee at the Mayo Foundation and by the Imperial Cancer Research Fund Animal Research Committee. To assess the efficacy of FMG expression in human tumors, athymic nude mice were injected with 106 human tumor cells to establish s.c. tumors. C57BL/6 mice were obtained from colonies bred at the Imperial Cancer Research Fund. Murine colorectal CMT93 cells or melanoma B16 cells were transfected with the PCR3-GALV or empty PCR3 plasmid. After 48 h, the cells were placed in selection, Geneticin (Life Technologies, Inc.), 1 mg/ml CMT93, and 5 mg/ml B16. A pooled population from each tumor line was obtained after 2 weeks. Two x 106 CMT93-GALV or CMT93-neo or 105 B16-GALV or B16-neo cells were inoculated s.c. into the flank region. Animals were examined daily, and the tumor was excised once it reached a diameter of 1.0 x 1.0 cm. At a time >14 days after primary excision, the mice were then rechallenged with parental tumor cells (s.c. injection on the opposite flank of 2 x 106 CMT93 or 105 B16). Animals were examined daily until tumor became palpable and killed if the tumor size reached 1.0 x 1.0 cm. An individual mouse was considered tumor free if the tumor was less than 0.3 x 0.3 cm.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Cytotoxic Effects of FMGs and Comparison to Suicide Genes.
We tested the cytotoxic activity of the cDNAs of envelope genes from three different classes of viruses: the rhabdoviral VSV-G envelope gene (11) , the combination of the F and H genes from measles virus (12) , and a hyperfusogenic version of the retroviral GALV in which the COOH-terminal R peptide sequence of the cytoplasmic domain of the envelope had been deleted.4 In transient transfections, the cytotoxicity of all three FMGs was superior to that of either the HSVtk or CD suicide genes when cells were plated at either low or high plating density, although cytotoxicity was greatest at high plating densities (Fig. 1A)Citation . GALV or the F and H combination was consistently the most potent gene (Fig. 1B)Citation when tested with HSVtk or CD in 10 human tumor lines/explants: Tel.CeB6 (human rhabdomyosarcoma) and HT1080 (human fibrosarcomas), 293, Mel624 (human melanoma), HeLa (cervical carcinoma), as well as in two freshly resected human colorectal and three freshly resected human melanoma explants (data not shown), confirming that the relative efficacies are not attributable to the selective choice of cell lines. The efficacy of VSV-G transfection approached that of either GALV or F+H when the ambient pH was reduced to <6.0 (data not shown). Moreover, transfections of GALV cDNA into cells blocked in S phase of the cell cycle using the drug aphidicolin showed that cytotoxicity is independent of the cell cycle (Fig. 1C)Citation .



View larger version (46K):
[in this window]
[in a new window]
  		Fig. 1. Expression of FMG cDNAs is highly cytotoxic in susceptible cell lines in a density-dependent fashion and has a bystander killing effect at least one log greater than HSVtk. A, 293 cells plated at a high seeding density (50,000 cells/well) were transfected with 5 µg of plasmid DNA (HSVtk, CD, F alone, or H alone) or cotransfected with 2.5 µg of F with 2.5 µg of H. Cells transfected with HSVtk or CD were incubated 24 h later in ganciclovir (5 µg/ml) or 5-fluorocytosine (3 µM). Surviving cell counts were determined using trypan blue exclusion cell counting or by lactate dehydrogenase release assays 5 days after transfection. Transfections with 5 µg of a control CMV-ß-gal plasmid showed a mean transfection efficiency of about 7%. Bars, SD. B, comparison of cytotoxicity of three FMGs with HSVtk at high plating density. 293 cells were transfected as in A with HSVtk, F and H together (F+H), GALV, or VSV-G. The results reported in A and B are representative of at least three separate experiments in each case. Bars, SD. C, arresting cells in S phase does not affect the efficiency of cell killing by FMG. Cells were preincubated in normal medium or medium containing 5 µg/ml of aphidicolin (Aphid) to block DNA synthesis. Twenty-four h later, the cells were transfected, in triplicates, with 5 µg of plasmid encoding GALV, no DNA, or GALV-EGF. GALV-EGF contains the EGF ligand NH2-terminally displayed on the fusogenic GALV protein, leading to >90% inhibition of its fusogenic capacity.4 Bars, SD. D, 293-ß-Gal cells were plated in triplicates in 96-well plates at a density of 105 cells/well. Twenty-four h later, increasing numbers of GALV-transfected (upper row of triplicates) or HSVtk-transfected (lower row) 293 cells were added to the wells. The number of transfected cells was estimated using transfection of parental 293 cells with CMV-ß-Gal 24 h previously. From left to right, the number of cells added per triplicate set of wells was 0, 1, 10, 100, 103, 104, and 105. Both FMG- and HSVtk-transfected wells were treated with GCV. Five days later, wells were washed and stained for ß-galactosidase as a measure of surviving cells. The data shown are representative of three similar experiments.

 
To compare directly the relative efficacies of the bystander effects of the FMG and the HSVtk suicide gene, Fig. 1DCitation shows that in excess of 104 HSVtk-transfected cells had to be added to wells containing 105 293-ß-Gal cells to come close to complete killing of the target population. In contrast, at least 1 log fewer GALV-transfected 293 cells were sufficient to eradicate completely the target population. Over several different experiments, we calculated that a single HSVtk-transfected cell would kill approximately 8–10 bystander cells at most under these particular conditions. However, a single GALV-expressing cell would kill, on average, in excess of 150–200 bystander cells. Similar data were obtained using the HT1080 and Mel624 cell lines, confirming that these effects are not specific to individual cell lines.

FMG Cytotoxicity Occurs Through Nonapoptotic Mechanisms.
Transfection with GALV induces the formation of multinucleated syncytia bounded by a single cellular membrane encompassing nuclei that individually still retain clearly defined nuclear membranes (Fig. 2A)Citation . Recruitment of bystander cells into the syncytium proceeds via a process that appears to involve streaming of the incoming nuclei along thick, organized microtubule bundles that feed into the perinuclear region such that large numbers of nuclei become localized in close juxtaposition (Fig. 2B)Citation . These structures can remain stable and metabolically and transcriptionally active for several days. At later time points, individual nuclei within the syncytia lose their nuclear membranes and release their chromosomes (Fig. 2D)Citation . The end result of the process, at least in vitro, is the disintegration of the syncytium with concomitant release of DNA (Fig. 2E)Citation .



View larger version (110K):
[in this window]
[in a new window]
  		Fig. 2. Syncytial formation proceeds through nuclear accumulation and fusion. Cells transfected with 5 µg of GALV plasmid DNA were followed by confocal microscopy for up to 120 h. Cells were stained with 4',6-diamidine-2'-phenylindole dihydrochloride to visualize the nuclei (blue/violet, A–C). A, a typical syncytium formed 24 h after transfection with GALV cDNA. The cellular membrane bounding the syncytium is shown as red staining (DII). B, transfected cells were stained with the DM1A antibody (Sigma), which recognizes {alpha}-tubulin as part of the cellular cytoskeleton. A single syncytium is shown 24 h after transfection. Incoming nuclei from newly fused cells can be seen being recruited at the periphery and being shuttled toward the accumulated nuclear concentration from previous fusions (top right). C, a syncytium at 48 h after transfection stained for apoptosis by the TUNEL assay (Boehringer Mannheim). Apoptotic nuclei appear as green staining at the periphery of the syncytium, but no positive staining was observed in the nuclei within syncytia. D and E, at late stages of syncytial formation, individual nuclei break down releasing chromosomes (D) until finally all nuclear structure is lost, leaving only chromosomes and interphase DNA (E).

 
At no stage of the sequence of syncytium development do nuclei stain positive for apoptosis by TUNEL analysis, although apoptotic cells or debris was occasionally observed at the periphery of well-developed syncytia (Fig. 2C)Citation . DNA ladders and electron microscopy also failed to indicate significant levels of apoptotic cell death in FMG-transfected as opposed to mock-transfected cultures (data not shown). Importantly, FMG-mediated tumor cell killing was not inhibited by the addition of caspase inhibitors, such as ZVAD, indicating that the mechanism of cell killing is not apoptotic (data not shown). We are currently investigating the dependence for killing on genes such as p53, p21, and other cell cycle controlling elements. This pattern of nonapoptotic cell killing has also been confirmed using the F+H combination and different cell lines (data not shown). The observation of interphase DNA and condensed chromosomes within syncytia (Fig. 2)Citation suggest that a process similar to premature chromosome condensation may be occurring in which fusion of dividing cells occurs with nondividing cells and eventually precipitates a mitosis-like state in the syncytium but from which other mitotic events cannot occur (13) , probably because the multiple nuclei can no longer organize an effective mitotic spindle.5

Established Tumors Can Be Eradicated by Transduction with Plasmid DNA Encoding FMG cDNA.
Human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90–100% of mice develop small, palpable tumors by 72 h after tumor cell seeding. Tumors were transfected with 10 µg of plasmid DNA complexed with Efectene lipid (Qiagen). The subsequent development of tumor growth was then measured with time as shown in Fig. 3Citation . Both HT1080 fibrosarcoma and Mel624 melanoma tumors transduced with the CMV-ß-Gal construct grew progressively in both tumor types (Fig. 3)Citation . In contrast, the CMV-GALV cDNA eradicated tumor growth in 100% of HT1080 and 90% of Mel624 tumor-bearing mice (Fig. 3C and D)Citation , despite the initial progression of the tumors after DNA transduction (Fig. 3A)Citation . Tumor-free mice in Fig. 3C and DCitation , were scored as having no palpable tumor mass by day 90 after initial tumor cell seeding; in addition, no outgrowths of tumor were observed in any of these mice over this period of 90 days. The in vivo delivery of the HSVtk gene, followed by treatment with GCV, was never capable of achieving similar levels of tumor killing (data not shown), even in immunocompetent models where the immune system boosts the antitumor efficacy of this treatment (14 , 15) . In subsequent experiments, we observed extensive syncytia in tumors recovered from mice that had received injections 48 h previously with FMG vector. No syncytia were observed from tumors injected with ß-Gal vector or PBS. In addition, RT-PCR studies from these tumors also showed the expression of hsps, molecules that are also associated with the fusion process (see below and Fig. 4Citation ). These observations strongly suggest that the in vivo mechanism of cell killing is the same as that seen in vitro. When tumors greater than 0.2–0.3 cm in diameter were injected with plasmid DNA, we were unable to obtain complete regressions of tumors with the same efficiency as seen in Fig. 3Citation . However, ongoing experiments with vectors of higher efficiency than plasmid DNA demonstrate that viral vectors are capable of eradicating larger established tumors.6



View larger version (12K):
[in this window]
[in a new window]
  		Fig. 3. Plasmid delivery of FMG cDNA can eliminate primary tumor growth, and toxicity can be controlled using a tissue-specific promoter. HT1080 (human fibrosarcoma) or Mel624 (human melanoma) tumors were seeded s.c. in nude mice and were transduced in situ with 10 µg/tumor of CMV-ß-Gal, CMV-GALV, or TYR-GALV plasmid DNA complexed with Efectene lipid (Qiagen; 10 mice/group). A, 7 days after DNA injection of HT1080 tumors, those injected with CMV-GALV plasmid began to regress compared with the progression of tumors in the other two groups. B, 13 days after transduction, some tumors reached 1.2 cm in the longest diameter, at which point those animals were sacrificed. The tumors in the CMV-GALV-injected group had all regressed and had been eliminated. C, by day 90 after transduction, nearly all mice in the CMV-ß-Gal and TYR-GALV groups developed tumors that reached 1.2 cm. Long-term tumor-free mice had no detectable tumor by the end of the experiment. D, progression of transduced human melanoma tumors, Mel624, was similar to that shown for the HT1080 tumors (A–C). By day 90 after transduction, both 90% of the tumors transduced with CMV-GALV; 100% of the tumors transduced with TYR-GALV had been eliminated, and no regrowths were observed.

 


View larger version (49K):
[in this window]
[in a new window]
  		Fig. 4. Expression of GALV induces hsp expression in human tumor cells and in murine tumor cells acts as an effective immunogen against parental tumor cell rechallenge. A, RT-PCR from TelCeB6 cells transfected with 5 µg of GALV plasmid, 24 h after transfection. Lane 1, {lambda} HindIII molecular weight markers; Lane 2, cDNA from TelCeB6 cells transfected with a nonfusogenic GALV-EGF plasmid using primers for inducible human hsp70; Lane 3, cDNA from TelCeB6 cells transfected with the GALV plasmid using primers for inducible human hsp70; Lanes 4 and 5 as for Lanes 2 and 3 using primers for human gp96; Lanes 6 and 7 as for Lanes 2 and 3 using primers for human glyceraldehyde-3-phosphate dehydrogenase as a positive control for RNA loading. Although hsp70 is not expressed in parental cells, gp96 has a basal level of expression that was not increased by transfection with the nonfusogenic GALV-EGF but was up-regulated by fusogenic GALV. B, murine colorectal CMT93 cells were transfected either with the pCR3-GALV plasmid or with the parental pCR3 plasmid lacking the GALV insert. Pooled populations of G418r cells were cloned. C57/BL mice were vaccinated with 2 x 106 CMT93-GALV or the same number of parental CMT93-neo, live tumor cells (injected s.c. into the flank). Both groups were rechallenged with 2 x 106 CMT93 parental cells on the opposite flank at least 2 weeks after the vaccination. Growth of the rechallenge was measured with time ({square}, mice vaccinated with CMT93-neo tumor cells; {diamond}, mice vaccinated with CMT93-GALV cells; 10 mice/group), and a tumor-free animal was scored if the tumor was less than 0.3 x 0.3 cm, this being the tumor size beyond which failure to develop tumor represents a genuine response to treatment in this model.

 
To address the issue of tumor specificity, we also constructed an expression vector in which the GALV cDNA is expressed from the human tyrosinase promoter, which we (16) and others (17) have previously shown confers tissue-specific expression to melanoma cells. Using a 300-bp sequence from this promoter as the core element (17) , HT1080 and Mel624 tumors were also transduced in vivo with the TYR-GALV plasmid (10 µg/tumor).7 HT1080 tumors continued to grow progressively after transduction with the TYR-GALV DNA (Fig. 3ACitation , Fig. 3BCitation , Fig. 3CCitation ). In contrast, Mel624 tumors were eradicated in 100% of the mice that received injections (Fig. 3D)Citation , indicating that transcriptional control of expression is an effective means of targeting FMG-mediated gene therapy to specific tumor types.

FMG Gene Expression Is Associated with Increased Expression of Immunostimulatory Signals and Acts as a Potent Immunogen.
The mechanisms by which tumor cells are killed influence the potency of the subsequent immune response to nontransduced tumors elsewhere in the animal (7 , 8 , 18) . Fig. 4Citation shows that FMG transfection is associated with induction of mRNA of two different heat shock proteins, hsp70 and gp96, both of which are known to play important roles in enhancing tumor immunogenicity (8 , 19) . Transfection of a nonfusogenic GALV-EGF cDNA did not induce either hsp over levels seen in resting cells (Fig. 4)Citation . These RT-PCR results were confirmed in three different cell lines (Tel.CeB6, HT1080, and Mel624) and by immunofluorescence (data not shown). In addition, the expression of viral FMGs would be expected to be highly immunogenic per se (that is separate from any effects of syncytial induction and hsp expression), which may itself promote generation of tumor-specific immunity, through cross-priming of APCs with tumor antigens. Murine cell lines are not fused by GALV as the murine homologue of the Pit-1 receptor is not recognized by GALV. Therefore, murine colorectal CMT93 (20) and melanoma B16 tumor cell lines were transfected with the GALV gene and transfected cells were used as live vaccine cells in syngeneic C57/BL mice. Both CMT93-GALV and B16-GALV tumors grew as primary tumors but at a reduced rate compared with the parental G418r CMT93-neo and B16-neo controls (data not shown). However, after surgery, animals vaccinated with GALV-expressing cells were significantly protected against rechallenge with parental, unmodified cells compared with animals vaccinated with parental cells transfected with neo alone (Fig. 4)Citation . Similar results were obtained with the B16 murine melanoma line (data not shown). These data confirm that expression of FMG in tumor cells can serve as a potent immunostimulatory signal that generates in vivo protection against unmodified parental tumor.


   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Our data show that FMG transfection is a much more effective treatment for killing human tumor lines in vitro than commonly used suicide genes. Killing is cell density dependent, independent of cell division, and does not require administration of a prodrug, thereby alleviating the problems of drug delivery and bioavailability. In addition, the local bystander effect of FMG killing is generally at least a log higher than that of HSVtk. Direct delivery of plasmid DNA encoding the GALV FMG to actively growing tumors in vivo is sufficient to eradicate tumor progression and growth, despite the relatively low efficiency of gene transfer.

Syncytial-mediated cell killing occurs by nonapoptotic mechanisms, through a process of nuclear recruitment, fusion, and disintegration and is associated with induction of hsps that should prove to be highly immune stimulatory in vivo (8 , 18) . In addition, expression of FMG is highly immunogenic per se (in the absence of syncytial induction), adding to the potency of the FMG as a mechanism for inducing antitumor immunization. Because neither GALV nor F+H fuse murine cells, we cannot yet assess fully the added contribution of syncytial induction to immune stimulation in an immunocompetent model. However, we are currently generating murine tumor lines and mice transgenic for the GALV receptor Pit-1 to address both these issues, as well as that of FMG-mediated toxicity to tissues surrounding targeted tumors. We have shown here that transcriptional targeting of FMG expression is possible to reduce toxicity, and we are currently developing molecular switches to ensure that FMG expression is extinguished when normal cells are recruited into the syncytia.


   ACKNOWLEDGMENTS
 
We thank A. Fielding, J. Salisbury, and R. B. Jenkins for helpful discussions, Suzanne Marie Facteau and Jill Ludvigson for animal care, and Toni Higgins for expert secretarial assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the Imperial Cancer Research Fund, London (to A. B., S. M, and R. V.), and the Mayo Foundation (to A. B., S. M., R. C., S. R., and R. V.). Back

2 To whom requests for reprints should be addressed at, Molecular Medicine Program, Guggenheim 18, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: (507) 284-9941; Fax: (507) 266-2122; E-mail: vile.richard{at}mayo.edu Back

3 The abbreviations used are: HSV/tk, herpes simplex virus thymidine kinase; GCV, ganciclovir; CD, cytosine deaminase; APC, antigen-presenting cell; FMG, fusogenic membrane glycoprotein; GALV, Gibbon ape leukemia virus; CMV, cytomegalovirus; TUNEL, terminal deoxynucleotidyltransferase-mediated nick end labeling; hsp, heat shock protein; ß-Gal, ß-galactosidase; RT-PCR, reverse transcription-PCR. Back

4 A. K. Fiedling, S. Chapel-Fernandez, M. P. Chadwick, F. I. Bullough, F-L. Cosset, and S. J. Russell. A hyperfusogenic Gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display, submitted for publication. Back

5 A. R. Bateman, K. S. Harrington, and R. G. Vile. Fusogenic membrane glycoproteins: investigation of the mechanism of syncitial formation and cytotoxicity, manuscript in preparation. Back

6 R. M. Diaz, A. R. Bateman, L. Emiliusen, D. Trono, S. J. Russell, and R. G. Vile. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy, manuscript in preparation. Back

7 Details of the expression vector are available on request. Back

Received 11/10/99. Accepted 1/31/00.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Moolten F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1994.[Medline]
  2. Peng K-W., Vile R. Vector development for cancer gene therapy. Tumor Targeting, 4: 3-11, 1999.
  3. Colombo M. P., Modesti A., Parmiani G., Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res., 52: 4853-4857, 1992.[Free Full Text]
  4. Pardoll D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415, 1995.[Medline]
  5. Huang A. Y. C., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow derived cells in presenting MHC Class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.[Abstract/Free Full Text]
  6. Cayeux S., Richter G., Becker C., Pezzutto A., Dorken B., Blankenstein T. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol., 29: 255-234, 1999.
  7. Vile R. G., Castleden S. C., Marshall J., Camplejohn R., Upton C., Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer, 71: 267-274, 1997.[Medline]
  8. Melcher A. A., Todryk S., Hardwick N., Ford M., Jacobson M., Vile R. G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med., 4: 581-587, 1998.[Medline]
  9. Todryk S., Melcher A. A., Hardwick N., Linardakis E., Bateman A., Colombo M. P., Stoppacciaro A., Vile R. G. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol., 163: 1398-1408, 1999.[Abstract/Free Full Text]
  10. Klasse P. J., Bron R., Marsh M. Mechanisms of enveloped virus entry into animal cells. Adv. Drug Delivery Rev., 34: 65-91, 1998.[Medline]
  11. Burns J. C., Friedmann T., Driever W., Burrascano M., Yee J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA, 90: 8033-8037, 1993.[Abstract/Free Full Text]
  12. Cathomen T., Naim H. Y., Cattaneo R. Measles virus with altered envelope protein cytoplasmic tails gain cell fusion competence. J. Virol., 72: 1224-1234, 1998.[Abstract/Free Full Text]
  13. Ghosh S., Paweletz N., Schroeter D. Cdc2-independent induction of premature mitosis by okadaic acid in HeLa cells. Exp. Cell Res., 242: 1-9, 1998.[Medline]
  14. Vile R. G., Hart I. R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res., 53: 3860-3864, 1993.[Abstract/Free Full Text]
  15. Vile R. G., Nelson J. A., Castleden S., Chong H., Hart I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res., 54: 6228-6234, 1994.[Abstract/Free Full Text]
  16. Diaz R. M., Eisen T., Hart I. R., Vile R. G. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J. Virol., 72: 789-795, 1998.[Abstract/Free Full Text]
  17. Bentley N. J., Eisen T., Goding C. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol., 14: 7996-8006, 1994.[Abstract/Free Full Text]
  18. Matzinger P. An innate sense of danger. Semin. Immunol., 10: 399-415, 1998.[Medline]
  19. Tamura Y., Peng P., Liu K., Daou M., Srivastava P. K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (Washington DC), 278: 117-120, 1997.[Abstract/Free Full Text]
  20. Chong H., Todryk S., Hutchinson G., Hart I. R., Vile R. G. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther., 5: 223-232, 1998.[Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Kottke, L. Sanchez-Perez, R. M. Diaz, J. Thompson, H. Chong, K. Harrington, S. K. Calderwood, J. Pulido, N. Georgopoulos, P. Selby, et al.
Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer
Cancer Res., December 15, 2007; 67(24): 11970 - 11979.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Hoffmann, W. Bayer, T. Grunwald, and O. Wildner
Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer
Mol. Cancer Ther., July 1, 2007; 6(7): 1942 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Li, A. Dutuor, L. Tao, X. Fu, and X. Zhang
Virotherapy with a Type 2 Herpes Simplex Virus-Derived Oncolytic Virus Induces Potent Antitumor Immunity against Neuroblastoma
Clin. Cancer Res., January 1, 2007; 13(1): 316 - 322.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Hoffmann and O. Wildner
Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy.
Mol. Cancer Ther., August 1, 2006; 5(8): 2013 - 2022.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. R. Simpson, Z. Han, B. Liu, Y. Wang, G. Campbell, and R. S. Coffin
Combination of a Fusogenic Glycoprotein, Prodrug Activation, and Oncolytic Herpes Simplex Virus for Enhanced Local Tumor Control.
Cancer Res., May 1, 2006; 66(9): 4835 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
C. A. Merten, J. Stitz, G. Braun, J. Medvedovska, K. Cichutek, and C. J. Buchholz
Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein
Nucleic Acids Res., March 15, 2006; 34(5): e41 - e41.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Errington, A. Bateman, T. Kottke, J. Thompson, K. Harrington, A. Merrick, P. Hatfield, P. Selby, R. Vile, and A. Melcher
Allogeneic Tumor Cells Expressing Fusogenic Membrane Glycoproteins as a Platform for Clinical Cancer Immunotherapy
Clin. Cancer Res., February 15, 2006; 12(4): 1333 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. P. Horn, S. Vongpunsawad, E. Kornmann, B. Fritz, D. P. Dittmer, R. Cattaneo, and M. Dobbelstein
Enhanced Cytotoxicity without Internuclear Spread of Adenovirus upon Cell Fusion by Measles Virus Glycoproteins
J. Virol., February 1, 2005; 79(3): 1911 - 1917.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Ebert, K. Shinozaki, C. Kournioti, M.-S. Park, A. Garcia-Sastre, and S. L. C. Woo
Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer
Cancer Res., May 1, 2004; 64(9): 3265 - 3270.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. Bateman, K. J. Harrington, T. Kottke, A. Ahmed, A. A. Melcher, M. J. Gough, E. Linardakis, D. Riddle, A. Dietz, C. M. Lohse, et al.
Viral Fusogenic Membrane Glycoproteins Kill Solid Tumor Cells by Nonapoptotic Mechanisms That Promote Cross Presentation of Tumor Antigens by Dendritic Cells
Cancer Res., November 15, 2002; 62(22): 6566 - 6578.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Linardakis, A. Bateman, V. Phan, A. Ahmed, M. Gough, K. Olivier, R. Kennedy, F. Errington, K. J. Harrington, A. Melcher, et al.
Enhancing the Efficacy of a Weak Allogeneic Melanoma Vaccine by Viral Fusogenic Membrane Glycoprotein-mediated Tumor Cell-Tumor Cell Fusion
Cancer Res., October 1, 2002; 62(19): 5495 - 5504.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
M. Bobkova, J. Stitz, M. Engelstadter, K. Cichutek, and C. J. Buchholz
Identification of R-peptides in envelope proteins of C-type retroviruses
J. Gen. Virol., September 1, 2002; 83(9): 2241 - 2246.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Fu and X. Zhang
Potent Systemic Antitumor Activity from an Oncolytic Herpes Simplex Virus of Syncytial Phenotype
Cancer Res., April 1, 2002; 62(8): 2306 - 2312.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
C. J. A. Ring
Cytolytic viruses as potential anti-cancer agents
J. Gen. Virol., March 1, 2002; 83(3): 491 - 502.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Grote, S. J. Russell, T. I. Cornu, R. Cattaneo, R. Vile, G. A. Poland, and A. K. Fielding
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice
Blood, June 15, 2001; 97(12): 3746 - 3754.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. L. Hammond, R. K. Plemper, J. Zhang, U. Schneider, S. J. Russell, and R. Cattaneo
Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen
J. Virol., March 1, 2001; 75(5): 2087 - 2096.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
H. Higuchi, S. F. Bronk, A. Bateman, K. Harrington, R. G. Vile, and G. J. Gores
Viral Fusogenic Membrane Glycoprotein Expression Causes Syncytia Formation with Bioenergetic Cell Death: Implications for Gene Therapy
Cancer Res., November 1, 2000; 60(22): 6396 - 6402.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bateman, A.
Right arrow Articles by Vile, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bateman, A.
Right arrow Articles by Vile, R. G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation